Diagnostic markers and prognostic factors in thyroid cancer

Future Oncology

Volumn 5, Issue 8, 2009, Pages 1283-1293

  Vriens, Menno R ^a   Schreinemakers, Jennifer M J ^a   Suh, Insoo ^a   Guerrero, Marlon A ^a   Clark, Orlo H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarkers; Gene expression profiling; Microrna; Somatic mutations; Thyroid cancer

Indexed keywords

B RAF KINASE; BETA CATENIN; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CALCITONIN; MATRIX METALLOPROTEINASE; MICRORNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN PATCHED; PROTEIN RET; RAS PROTEIN; THYROGLOBULIN; TRANSCRIPTION FACTOR PAX8; TUMOR MARKER;

ASPIRATION BIOPSY; CANCER STAGING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HYPERPLASIA; IMMUNOREACTIVITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; THYROID CANCER; THYROIDECTOMY;

HUMANS; PROGNOSIS; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 75649124886     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.85     Document Type: Review

References (66)

1. Davies L, Welch HG: Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295(18), 2164-2167 (2006).
2. Kondo T, Ezzat S, Asa SL: Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat. Rev. Cancer 6(4), 292-306 (2006).
3. Enewold L, Zhu K, Ron E et al.: Rising thyroid cancer incidence in the united States by tumor characteristics, 1980-2005. Cancer Epidemiol. Biomarkers Prev. 18(3), 784-791 (2009).
4. Shibru D, Chung K, Kebebew E: Recent developments in the clinical application of thyroid cancer biomarkers. Curr. Opin. Oncol. 20, 13-18 (2008).
5. Prasad NB, Somervell H, Tufano RP et al.: Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin. Cancer Res. 14(11), 3327-3337 (2008). ■■ Highlights the importance of a panel of biomarkers for thyroid cancer.
6. Rydlova M, Ludvikova M, Stankova I: Potential diagnostic markers in nodular lesions of the thyroid gland: an immunohistochemical study. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub. 152(110), 53-60 (2008).
7. Henry JF, Denizot A, Puccini M et al.: Latent subclinical medullary thyroid carcinoma: diagnosis and treatment. World J. Surg. 22(7), 752-756; discussion 756-757 (1998).
8. Chatterjee SK, Zetter BR: Cancer biomarkers: knowing the present and predicting the future. Future Oncol. 1, 37-50 (2005).
9. Costante G, Durante C, Francis Z, Schlumberger M, Filetti S: Determination of calcium of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. Nat. Clin. Pract. Endocrinol. Metab. 5, 35-44 (2009).
10. Zagorianakou P, Malamou-Mitsi V, Zagorianakou N et al.: The role of fine-needle aspiration biopsy in the management of patients with thyroid nodules. In vivo 19(3), 605-609 (2005).
11. Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, LoPresti JS: Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J. Clin. Endocrinol. Metab. 90(10), 5566-5575 (2005).
12. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY: Staging systems for papillary thyroid carcinoma: a review and comparison. Ann. Surg. 245(3), 366-378 (2007). ■ Review of all current staging systems.
13. Passler C, Prager G, Scheuba C, Kaserer K, Zettinig G, Niederle B: Application of staging systems for differentiated thyroid carcinoma in an endemic goiter region with iodine substitution. Ann. Surg. 2, 227-234 (2003).
14. Byar DP, Green SB, Dor P et al.: A prognostic index for thyroid carcinoma: a study of the EORTC thyroid cancer cooperative group. Eur. J. Cancer 15, 1033-1041 (1979).
15. Layfield L, Cibas ES, Gharib H, Mandel SJ: Thyroid aspiration cytology: current status. CA Cancer J. Clin. 59, 99-110 (2009).
16. Vriens MR, Sabanci U, Epstein HD et al.: Reliability of fine-needle aspiration in patients with familial nonmedullary thyroid cancer. Thyroid 9, 1011-1016 (1999).
17. Nikiforov Y, Steward DL, Robinson-Smith TM et al.: Molecular testing for mutations in improving the fine needle aspiration diagnosis of thyroid nodules. J. Clin. Endocrin. Metab. 94(6), 2092-2098 (2009). ■ Emphazises the importance of molecular testing of thyroid nodules.
18. Baloch ZW, LiVolsi VA, Asa SL et al.: Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn. Cytopathol. 36, 425-437 (2008).
19. Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A: ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy. Ann. Surg. 242, 353-363 (2005).
20. Kebebew E: Thyroid oncogenesis. In: Textbook of Endocrine Surgery, 2nd Edition Clark O, Duh Q-Y, Kebebew E (Eds). Elsevier Saunders Company, PA, USA, Chapter 31 (2006).
21. Henderson Y, Shellenberger TD, Williams MD et al.: High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin. Cancer Res. 15, 485-491 (2009).
22. Wellbrock C, Karasarides M, Marais R: The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol. 5, 875-885 (2004).
23. Wojciechowska K, Lewinski A: BRAF mutations in papillary thyroid carcinoma. Endocr. Regul. 40, 129-138 (2006).
24. Mitsiades CS, Negri J, McMullan C, McMillan DW, Sozopoulos E, Fanourakis G et al.: Targeting BRAFV600E in thyroid carcinoma: therapeutic implications. Mol. Cancer Ther. 6(3), 1070-1078 (2007).
25. Nikiforov YE: Thyroid carcinoma: molecular pathways and therapeutic targets. Mod. Pathol. 21, S37-S43 (2008).
26. Kebebew E, Weng J, Bauer J et al.: The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann. Surg.246, 466-471 (2007). ■■ Emphasizes the role of BRAF mutation ana lysis for therapy and follow-up monitoring.
27. Chung KW, Yang SK, Lee GK et al.: Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin. Endocrinol. 65(5), 660-666 (2006).
28. Fagin JA, Mitsiades N: Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract. Res. Clin. Endocrinol. Metab. 22(6), 955-969 (2008).
29. Nikiforova MN, Lynch RA, Biddinger PW et al.: RAS point mutations and PAX8-PPARγrearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J. Clin. Endocrinol. Metab. 88, 2318-2326 (2003).
30. Garcia-Rostan G, Zhao H, Camp RL et al.: Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J. Clin. Oncol. 21, 3226-3235 (2003).
31. Basolo F, Pisatura F, Pollina LE et al.: N-ras mutation in poorly differentiated thyroid carcinoma: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid 10, 19-23 (2000).
32. Kroll TG, Sarraf P, Pecciarini L et al.: PAX8-PPARγ1 fusion oncogene in human thyroid carcinoma [corrected]. Science 289, 1357-1360 (2000).
33. Placzkowski KA, Reddi HV, Grebe SKG, Eberhardt NE, McIver B: The role of the PAX8/PPARγ fusion oncogene in thyroid cancer. PPAR Res. (2008) (Epub ahead of print).
34. Sapio MR, Posca D, Raggioli A et al.: Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin. Endocrinol. 66, 678-683 (2007).
35. Xing M, Tufano RP, Tufaro AP et al.: Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 89(6), 2867-2872, 2004.
36. Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL, Tallini G: β-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am. J. Pathol. 158(3), 987-996 (2001).
37. Huang Y, Prasad M, Lemon WJ et al.: Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc. Natl Acad. Sci. USA 98, 15044-15049 (2001). ■■ Reveals the clinical use of gene expression in papillary thyroid cancer.
38. Jarzab B, Wiench M, Fujarewicz K et al.: Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res. 65, 1587-1597 (2005).
39. Barden CB, Shister KW, Zhu B et al.: Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clin. Cancer Res. 9, 1792-1800 (2003).
40. Mazzanti C, Zeiger MA, Costouros NG et al.: Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res. 64, 2898-2903 (2004).
41. Kebebew E, Peng M, Reiff E, McMillan A: Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms. Cancer 106, 2592-2597 (2006).
42. Franco C, Martinez V, Allamand J et al.: Molecular markers in thyroid fine-needle aspiration biopsy: a prospective study. Appl. Immunohistochem. Mol. Morphol. 17, 211-215 (2009).
43. Weber KB, Shroyer KR, Heinz DE et al.: The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am. J. Clin. Pathol. 122, 524 -531 (2004).
44. Herrmann ME, LiVolsi VA, Pasha TL et al.: Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch. Pathol. Lab. Med. 126, 710-713 (2002).
45. Volante M, Bozzalla-Cassione F, DePompa R et al.: Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid. Virchows Arch. 445, 183-188 (2004).
46. Nga ME, Lim GS, Soh CH, Kumarasinghe MP: HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma. Diagn. Cytopathol. 36, 550-556 (2008).
47. Umbricht CB, Conrad GT, Clark DP et al.: Human telomerase reverse transcriptase gene expression and the surgical management of suspicious thyroid tumors. Clin. Cancer Res. 10, 5762-5768 (2004).
48. Yossie Asato de Camargo R, Longatto Filho A, Alves VA et al.: Lactoferrin in thyroid lesions: immunoreactivity in fine needle aspiration biopsy samples. Acta Cytol. 40, 408-413 (1996).
49. Baldini E, Toller M, Graziano FM et al.: Expression of matrix metalloproteinases and their specific inhibitors in normal and different human thyroid tumor cell lines. Thyroid 14(11), 881-888 (2004).
50. Ito Y, Yoshida H, Kakudo K et al.: Inverse relationships between the expression of MMP-7 and MMP-11 and predictors of poor prognosis of papillary thyroid carcinoma. Pathology 38(5), 421-425 (2006).
51. Yeh MW, Rougier JP, Park JW et al.: Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A. Endocr. Relat. Cancer 13(4), 1173-1183 (2006).
52. Tian X, Cong M, Zhou W et al.: Relationship between protein expression of VEGF-C, MMP-2 and lymph node metastasis in papillary thyroid cancer. J. Int. Med. Res. 36(4), 699-703 (2008).
53. Maeta H, Ohgi S, Terada T: Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas. Virchows Arch. 438(2), 121-128 (2001).
54. Cavalheiro BG, Junqueira CR, Brandão LG: Expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinase 2 (TIMP-2) in medullary thyroid carcinoma: prognostic implications. Thyroid 18(8), 865-871 (2008).
55. Komorowski J, Pasieka Z, Jankiewicz-Wika J, Stepien H: Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer. Thyroid 12(8), 655-662 (2002).
56. Cavalheiro BG, Junqueira CR, Brandão LG: Expression of membrane type 1 matrix metalloproteinase in medullary thyroid carcinoma: prognostic implications. Head Neck DOI 10.1002/hed.21146 (2009) (Epub ahead of print).
57. Nikiforova MN, Chiosea SI, Nikiforov YE: MicroRNA expression profiles in thyroid tumors. Endocr Pathol 20(2), 85-91 (2009). ■ Reviews the existing findings of miRNA deregulation in thyroid tumors.
58. Slack FJ, Weidhaas JB: MicroRNA in cancer prognosis. N. Eng. J. Med. 359, 2720-2722 (2008).
59. Calin GA, Sevignani C, Dumitru CD et al.: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl Acad. Sci. USA 101, 2999-3004 (2004).
60. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE: MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J. Clin. Endocrinol. Metab. 93 (5), 1600-1608, (2008).
61. He H, Jazdzewski K, Li W et al.: The role of microRNA genes in papillary thyroid carcinoma. Proc. Natl Acad. Sci. USA 102(52), 19075-19080 (2005).
62. Pallante P, Visone R, Ferracin M et al.: MicroRNA deregulation in human thyroid papillary carcinomas. Endocr. Relat. Cancer 13(2), 497-508 (2006).
63. Tetzlaff MT, Liu A, Xu X et al.: Differential expression of miRNAs in papillary thyroid carcinoma compared to ultinodular goiter using formalin fixed paraffin embedded tissues. Endocr. Pathol. 18(3), 163-173 (2007).
64. Visone R, Pallante P, Vecchione A et al.: Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 26(54), 7590-7595 (2007).
65. Weber F, Teresi RE, Broelsch CE, Frilling A, Eng C: A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. J. Clin. Endocrinol. Metab. 91(9), 3584-3591 (2006).
66. Chen YT, Kitabayashi N, Zhou XK, Fahey TJ III, Scognamiglio T: MicroRNA ana lysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod. Pathol. 21(9), 1139-1146 (2008).